0001179110-14-009095.txt : 20140523 0001179110-14-009095.hdr.sgml : 20140523 20140523194412 ACCESSION NUMBER: 0001179110-14-009095 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140521 FILED AS OF DATE: 20140523 DATE AS OF CHANGE: 20140523 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 BUSINESS PHONE: 508-975-4820 MAIL ADDRESS: STREET 1: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PAKIANATHAN DEEPIKA CENTRAL INDEX KEY: 0001270734 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 14868291 MAIL ADDRESS: STREET 1: 3000 SAND HILL RD, BLDG 1, STE 135 STREET 2: C/O DELPHI VENTURES CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 edgar.xml FORM 4 - X0306 4 2014-05-21 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001270734 PAKIANATHAN DEEPIKA DELPHI VENTURES, 3000 SAND HILL RD, BLDG 1, STE 135 MENLO PARK CA 94025 1 0 0 0 Common Stock 2014-05-21 4 P 0 91754 26.194 A 2174550 I By Delphi Ventures VIII, L.P. Common Stock 2014-05-21 4 P 0 896 26.194 A 21233 I By Delphi BioInvestments VIII, L.P. Common Stock 2014-05-22 4 P 0 19807 26.0902 A 2194357 I By Delphi Ventures VIII, L.P. Common Stock 2014-05-22 4 P 0 193 26.0902 A 21426 I By Delphi BioInvestments VIII, L.P. Common Stock 2014-05-23 4 P 0 1752 26.4466 A 2196109 I By Delphi Ventures VIII, L.P. Common Stock 2014-05-23 4 P 0 17 26.4466 A 21443 I By Delphi BioInvestments VIII, L.P. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.92 to $26.25, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C ("DMP"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi Funds"). As a managing member of DMP, the Reporting Person shares voting and investment power over the shares held by the Delphi Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi Funds, except to the extent of her proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.98 to $26.25, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.41 to $26.45, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4. /s/ Matthew T. Potter, Attorney-in-Fact for Deepika R. Pakianathan 2014-05-23